Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT04383938
Title Phase 1/2 Study of APR-246 in Combination With Pembrolizumab in Subjects With Solid Tumor Malignancies
Recruitment Completed
Gender both
Phase Phase Ib/II
Variant Requirements No
Sponsors Aprea Therapeutics

transitional cell carcinoma

Advanced Solid Tumor

bladder urothelial carcinoma

stomach cancer

lung non-small cell carcinoma

gastroesophageal junction adenocarcinoma


APR-246 + Pembrolizumab

Age Groups: adult | senior
Covered Countries USA

No variant requirements are available.